Shopping Cart 0
Cart Subtotal
USD 0

Type 1 Diabetes (Juvenile Diabetes)-Pipeline Review, H1 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 5000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 7500

Details

Type 1 Diabetes (Juvenile Diabetes)-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Type 1 Diabetes (Juvenile Diabetes)-Pipeline Review, H1 2017, provides an overview of the Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline landscape.

Type 1 diabetes (T1D) is an autoimmune disease in which a pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body's immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. Risk factors of type 1 diabetes include genetics and family history, diseases of the pancreas and infection or illness. The signs and symptoms of type 1 diabetes include increased thirst and frequent urination, extreme hunger, weight loss, fatigue, irritability or unusual behavior.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Type 1 Diabetes (Juvenile Diabetes)-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 9, 32, 26, 2, 113, 34 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 2, 32 and 5 molecules, respectively.

Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).

The pipeline guide reviews pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 7

Type 1 Diabetes (Juvenile Diabetes)-Overview 8

Type 1 Diabetes (Juvenile Diabetes)-Therapeutics Development 9

Type 1 Diabetes (Juvenile Diabetes)-Therapeutics Assessment 37

Type 1 Diabetes (Juvenile Diabetes)-Companies Involved in Therapeutics Development 50

Type 1 Diabetes (Juvenile Diabetes)-Drug Profiles 103

Type 1 Diabetes (Juvenile Diabetes)-Dormant Projects 529

Type 1 Diabetes (Juvenile Diabetes)-Discontinued Products 537

Type 1 Diabetes (Juvenile Diabetes)-Product Development Milestones 539

Appendix 548


List Of Figure

List of Figures

Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017


List Of Table

List of Tables

Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Products under Development by Companies, H1 2017 (Contd..11), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Adocia, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by AiCuris GmbH & Co KG, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Alteogen Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Amarantus Bioscience Holdings Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Amarna Therapeutics BV, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by AntriaBio Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by apceth Biopharma GmbH, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Aphios Corp, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Araim Pharmaceuticals Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Argos Therapeutics Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Astellas Pharma Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by AstraZeneca Plc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Athersys Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Atlantic Bio Sci LLC, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Axxam SpA, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Beta-Cell NV, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Biocon Ltd, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by BioLineRx Ltd, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by BioLingus AG, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Biozeus, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by BirchBioMed Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Boehringer Ingelheim GmbH, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Caladrius Biosciences Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Cancer Prevention Pharmaceuticals Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Compugen Ltd, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by ConjuChem LLC, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Dance Biopharm Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Denceptor Therapeutics Ltd, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Diabetology (Products) Ltd, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by DiaMedica Therapeutics Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Diamyd Medical AB, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Diasome Pharmaceuticals Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by DiaVacs Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Dompe Farmaceutici SpA, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Eli Lilly and Company, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Ensol Biosciences Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by EpiVax Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Escape Therapeutics Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Evotec AG, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Fate Therapeutics Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Generex Biotechnology Corp, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by GeNeuro SA, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Geropharm LLC, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Gilead Sciences Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by GlaxoSmithKline Plc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Grifols SA, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Heptares Therapeutics Ltd, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by ImmusanT Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Innopharmax Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Intrexon Corp, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Ixchel Pharma LLC, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Johnson & Johnson, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Kadimastem Ltd, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Kamada Ltd, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Kasiak Research Pvt Ltd, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by KPI Therapeutics Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Lexicon Pharmaceuticals Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Ligand Pharmaceuticals Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Lonestar Heart Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by MacroGenics Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Medestea Research & Production SpA, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by MedImmune LLC, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Medtronic Plc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Medy-Tox Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Melior Discovery Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Merck & Co Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Meridigen Biotech Co Ltd, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Neovacs SA, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Novo Nordisk A/S, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Noxxon Pharma AG, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Oramed Pharmaceuticals Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Orgenesis Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by OSE Immunotherapeutics, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Parvus Therapeutics Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Pathfinder Cell Therapy Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Pfizer Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by PharmaCyte Biotech Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by PharmaIN Corp, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Prometheon Pharma LLC, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Purzer Pharmaceutical Co Ltd, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by RedHill Biopharma Ltd, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by REGiMMUNE Corp, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Sanofi, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Selecta Biosciences Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Semma Therapeutics Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Sevion Therapeutics Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Sotio AS, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Tetragenetics Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Thermalin Diabetes LLC, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Toleranzia AB, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Transgene Biotek Ltd, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Traverse Biosciences Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by UCB SA, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Unicyte AG, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by United Therapeutics Corp, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by ViaCyte Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by XL-protein GmbH, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by XOMA Corp, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Zealand Pharma AS, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Dormant Projects, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Dormant Projects, H1 2017 (Contd..1), H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Dormant Projects, H1 2017 (Contd..2), H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Dormant Projects, H1 2017 (Contd..3), H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Dormant Projects, H1 2017 (Contd..4), H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Dormant Projects, H1 2017 (Contd..5), H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Dormant Projects, H1 2017 (Contd..6), H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Dormant Projects, H1 2017 (Contd..7), H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Discontinued Products, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Discontinued Products, H1 2017 (Contd..1), H1 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Adocia, AiCuris GmbH & Co KG, Alteogen Inc, Amarantus Bioscience Holdings Inc, Amarna Therapeutics BV, AntriaBio Inc, apceth Biopharma GmbH, Aphios Corp, Araim Pharmaceuticals Inc, Argos Therapeutics Inc, Astellas Pharma Inc, AstraZeneca Plc, Athersys Inc, Atlantic Bio Sci LLC, Axxam SpA, Beta-Cell NV, Biocon Ltd, BioLineRx Ltd, BioLingus AG, Biozeus, BirchBioMed Inc, Boehringer Ingelheim GmbH, Caladrius Biosciences Inc, Cancer Prevention Pharmaceuticals Inc, Compugen Ltd, ConjuChem LLC, Daewoong Pharmaceutical Co Ltd, Dance Biopharm Inc, Denceptor Therapeutics Ltd, Diabetology (Products) Ltd, DiaMedica Therapeutics Inc, Diamyd Medical AB, Diasome Pharmaceuticals Inc, DiaVacs Inc, Dompe Farmaceutici SpA, Eli Lilly and Company, Ensol Biosciences Inc, EpiVax Inc, Escape Therapeutics Inc, Evotec AG, Fate Therapeutics Inc, Generex Biotechnology Corp, GeNeuro SA, Geropharm LLC, Gilead Sciences Inc, GlaxoSmithKline Plc, Grifols SA, Hanmi Pharmaceuticals Co Ltd, Heptares Therapeutics Ltd, ImmusanT Inc, Innopharmax Inc, Intrexon Corp, Ixchel Pharma LLC, Johnson & Johnson, Kadimastem Ltd, Kamada Ltd, Kasiak Research Pvt Ltd, KPI Therapeutics Inc, Lexicon Pharmaceuticals Inc, Ligand Pharmaceuticals Inc, Lonestar Heart Inc, MacroGenics Inc, Medestea Research & Production SpA, MedImmune LLC, Medtronic Plc, Medy-Tox Inc, Melior Discovery Inc, Merck & Co Inc, Meridigen Biotech Co Ltd, Mitsubishi Tanabe Pharma Corp, Neovacs SA, Novo Nordisk A/S, Noxxon Pharma AG, Oramed Pharmaceuticals Inc, Orgenesis Inc, OSE Immunotherapeutics, Paras Biopharmaceuticals Finland Oy, Parvus Therapeutics Inc, Pathfinder Cell Therapy Inc, Pfizer Inc, PharmaCyte Biotech Inc, PharmaIN Corp, Prometheon Pharma LLC, Purzer Pharmaceutical Co Ltd, RedHill Biopharma Ltd, REGiMMUNE Corp, Sanofi, Selecta Biosciences Inc, Semma Therapeutics Inc, Sevion Therapeutics Inc, Sotio AS, Tetragenetics Inc, Thermalin Diabetes LLC, Toleranzia AB, Transgene Biotek Ltd, Traverse Biosciences Inc, UCB SA, Unicyte AG, United Therapeutics Corp, ViaCyte Inc, XL-protein GmbH, XOMA Corp, Zealand Pharma AS, Zensun (Shanghai) Sci & Tech Co Ltd

Company Profile

Company Profile Title

Type 1 Diabetes (Juvenile Diabetes)-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Type 1 Diabetes (Juvenile Diabetes)-Pipeline Review, H1 2017, provides an overview of the Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline landscape.

Type 1 diabetes (T1D) is an autoimmune disease in which a pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body's immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. Risk factors of type 1 diabetes include genetics and family history, diseases of the pancreas and infection or illness. The signs and symptoms of type 1 diabetes include increased thirst and frequent urination, extreme hunger, weight loss, fatigue, irritability or unusual behavior.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Type 1 Diabetes (Juvenile Diabetes)-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 9, 32, 26, 2, 113, 34 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 2, 32 and 5 molecules, respectively.

Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).

The pipeline guide reviews pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

Introduction 7

Type 1 Diabetes (Juvenile Diabetes)-Overview 8

Type 1 Diabetes (Juvenile Diabetes)-Therapeutics Development 9

Type 1 Diabetes (Juvenile Diabetes)-Therapeutics Assessment 37

Type 1 Diabetes (Juvenile Diabetes)-Companies Involved in Therapeutics Development 50

Type 1 Diabetes (Juvenile Diabetes)-Drug Profiles 103

Type 1 Diabetes (Juvenile Diabetes)-Dormant Projects 529

Type 1 Diabetes (Juvenile Diabetes)-Discontinued Products 537

Type 1 Diabetes (Juvenile Diabetes)-Product Development Milestones 539

Appendix 548


List Of Figure

List of Figures

Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017


List Of Table

List of Tables

Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Products under Development by Companies, H1 2017 (Contd..11), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Adocia, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by AiCuris GmbH & Co KG, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Alteogen Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Amarantus Bioscience Holdings Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Amarna Therapeutics BV, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by AntriaBio Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by apceth Biopharma GmbH, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Aphios Corp, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Araim Pharmaceuticals Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Argos Therapeutics Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Astellas Pharma Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by AstraZeneca Plc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Athersys Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Atlantic Bio Sci LLC, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Axxam SpA, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Beta-Cell NV, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Biocon Ltd, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by BioLineRx Ltd, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by BioLingus AG, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Biozeus, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by BirchBioMed Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Boehringer Ingelheim GmbH, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Caladrius Biosciences Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Cancer Prevention Pharmaceuticals Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Compugen Ltd, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by ConjuChem LLC, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Dance Biopharm Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Denceptor Therapeutics Ltd, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Diabetology (Products) Ltd, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by DiaMedica Therapeutics Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Diamyd Medical AB, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Diasome Pharmaceuticals Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by DiaVacs Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Dompe Farmaceutici SpA, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Eli Lilly and Company, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Ensol Biosciences Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by EpiVax Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Escape Therapeutics Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Evotec AG, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Fate Therapeutics Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Generex Biotechnology Corp, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by GeNeuro SA, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Geropharm LLC, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Gilead Sciences Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by GlaxoSmithKline Plc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Grifols SA, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Heptares Therapeutics Ltd, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by ImmusanT Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Innopharmax Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Intrexon Corp, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Ixchel Pharma LLC, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Johnson & Johnson, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Kadimastem Ltd, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Kamada Ltd, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Kasiak Research Pvt Ltd, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by KPI Therapeutics Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Lexicon Pharmaceuticals Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Ligand Pharmaceuticals Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Lonestar Heart Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by MacroGenics Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Medestea Research & Production SpA, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by MedImmune LLC, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Medtronic Plc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Medy-Tox Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Melior Discovery Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Merck & Co Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Meridigen Biotech Co Ltd, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Neovacs SA, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Novo Nordisk A/S, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Noxxon Pharma AG, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Oramed Pharmaceuticals Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Orgenesis Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by OSE Immunotherapeutics, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Parvus Therapeutics Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Pathfinder Cell Therapy Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Pfizer Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by PharmaCyte Biotech Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by PharmaIN Corp, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Prometheon Pharma LLC, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Purzer Pharmaceutical Co Ltd, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by RedHill Biopharma Ltd, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by REGiMMUNE Corp, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Sanofi, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Selecta Biosciences Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Semma Therapeutics Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Sevion Therapeutics Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Sotio AS, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Tetragenetics Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Thermalin Diabetes LLC, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Toleranzia AB, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Transgene Biotek Ltd, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Traverse Biosciences Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by UCB SA, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Unicyte AG, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by United Therapeutics Corp, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by ViaCyte Inc, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by XL-protein GmbH, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by XOMA Corp, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Zealand Pharma AS, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Dormant Projects, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Dormant Projects, H1 2017 (Contd..1), H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Dormant Projects, H1 2017 (Contd..2), H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Dormant Projects, H1 2017 (Contd..3), H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Dormant Projects, H1 2017 (Contd..4), H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Dormant Projects, H1 2017 (Contd..5), H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Dormant Projects, H1 2017 (Contd..6), H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Dormant Projects, H1 2017 (Contd..7), H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Discontinued Products, H1 2017

Type 1 Diabetes (Juvenile Diabetes)-Discontinued Products, H1 2017 (Contd..1), H1 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Adocia, AiCuris GmbH & Co KG, Alteogen Inc, Amarantus Bioscience Holdings Inc, Amarna Therapeutics BV, AntriaBio Inc, apceth Biopharma GmbH, Aphios Corp, Araim Pharmaceuticals Inc, Argos Therapeutics Inc, Astellas Pharma Inc, AstraZeneca Plc, Athersys Inc, Atlantic Bio Sci LLC, Axxam SpA, Beta-Cell NV, Biocon Ltd, BioLineRx Ltd, BioLingus AG, Biozeus, BirchBioMed Inc, Boehringer Ingelheim GmbH, Caladrius Biosciences Inc, Cancer Prevention Pharmaceuticals Inc, Compugen Ltd, ConjuChem LLC, Daewoong Pharmaceutical Co Ltd, Dance Biopharm Inc, Denceptor Therapeutics Ltd, Diabetology (Products) Ltd, DiaMedica Therapeutics Inc, Diamyd Medical AB, Diasome Pharmaceuticals Inc, DiaVacs Inc, Dompe Farmaceutici SpA, Eli Lilly and Company, Ensol Biosciences Inc, EpiVax Inc, Escape Therapeutics Inc, Evotec AG, Fate Therapeutics Inc, Generex Biotechnology Corp, GeNeuro SA, Geropharm LLC, Gilead Sciences Inc, GlaxoSmithKline Plc, Grifols SA, Hanmi Pharmaceuticals Co Ltd, Heptares Therapeutics Ltd, ImmusanT Inc, Innopharmax Inc, Intrexon Corp, Ixchel Pharma LLC, Johnson & Johnson, Kadimastem Ltd, Kamada Ltd, Kasiak Research Pvt Ltd, KPI Therapeutics Inc, Lexicon Pharmaceuticals Inc, Ligand Pharmaceuticals Inc, Lonestar Heart Inc, MacroGenics Inc, Medestea Research & Production SpA, MedImmune LLC, Medtronic Plc, Medy-Tox Inc, Melior Discovery Inc, Merck & Co Inc, Meridigen Biotech Co Ltd, Mitsubishi Tanabe Pharma Corp, Neovacs SA, Novo Nordisk A/S, Noxxon Pharma AG, Oramed Pharmaceuticals Inc, Orgenesis Inc, OSE Immunotherapeutics, Paras Biopharmaceuticals Finland Oy, Parvus Therapeutics Inc, Pathfinder Cell Therapy Inc, Pfizer Inc, PharmaCyte Biotech Inc, PharmaIN Corp, Prometheon Pharma LLC, Purzer Pharmaceutical Co Ltd, RedHill Biopharma Ltd, REGiMMUNE Corp, Sanofi, Selecta Biosciences Inc, Semma Therapeutics Inc, Sevion Therapeutics Inc, Sotio AS, Tetragenetics Inc, Thermalin Diabetes LLC, Toleranzia AB, Transgene Biotek Ltd, Traverse Biosciences Inc, UCB SA, Unicyte AG, United Therapeutics Corp, ViaCyte Inc, XL-protein GmbH, XOMA Corp, Zealand Pharma AS, Zensun (Shanghai) Sci & Tech Co Ltd